1. PacBio (PACB) enters high-throughput carrier screening market with expanded PureTarget portfolio, streamlining multiple assays into a single scalable test powered by HiFi sequencing technology.
2. PacBio’s PureTarget panels offer flexibility for labs worldwide, enabling throughput of up to 100,000 samples annually on a single Revio system, catering to clinical programs and national-scale initiatives.
3. Industry prospects favoring PACB as global carrier screening market expected to grow at a CAGR of 12.4% from 2023 to 2030, driven by increased investment in genetic testing and demand for cost-efficient technologies.
4. Latest updates from PACB’s peers like Illumina, Thermo Fisher, and QIAGEN showcasing advancements in NGS, proteomics, sample prep, and genomic profiling, highlighting industry trends and competition in genomics solutions.
5. Zacks Investment Research releases 7 elite stocks, including PACB, deemed "Most Likely for Early Price Pops" based on strong buy rankings, offering potential for investors seeking high-growth opportunities in the medical sector.

Read more at Nasdaq: PacBio Enters Carrier Screening Market With PureTarget Expansion